Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 2

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 2
---
 long-acting local analgesic approved for infiltration, field block, interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block.                                                                                                                          | ​ | ​ | ​ | ZILRETTA®(triamcinolone acetonide extended-release injectable suspension) is the first and only extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis knee pain.          
 ZILRETTA employs a proprietary microsphere technology combining triamcinolone acetonide—a commonly administered, immediate-release corticosteroid—with a poly lactic-co- glycolic acid matrix to provide extended pain relief. | ​ | ​ | ​ | The iovera®º system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific nerve to interrupt its ability to transmit a pain signal. Results can be felt immediately after ioveraº treatment with pain relief that can last three months, and in some cases longer, as the nerve regenerates over time. | ​ |

TABLE OF CONTENTS FRANK D. LEE
Chief Executive Officer To Our Stockholders, 2024 Accomplishments We made considerable progress throughout 2024, which leaves us well-positioned for success in 2025 and beyond. We achieved record revenues of $701 million, the high end of our guided range. We secured separate Centers for Medicare & Medicaid Services (CMS) coverage and product-specific reimbursement codes for both EXPAREL and iovera. In the clinic, we reported compelling two-year data from our 72-patient Phase 1 study of PCRX-201, which also received the first ever Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for a gene therapy product candidate. Importantly, we established a best-practice Commercial, Market Access, and Medical Powerhouse to drive topline growth. We enter 2025 with a sharp focus on growth, operational excellence and a clear mission to deliver innovative, non-opioid pain therapies to transform the lives of patients. With a best-in-class commercial portfolio that is producing significant cash flow, we believe we are well equipped to extend our leadership in non-opioid pain management and transform Pacira into an innovative biopharmaceutical organization with a robust pipeline to support